FDA Advisory Panel Spurns Pacira's Request for Expanded Use of Pain Drug Exparel By Sam | February 15, 2018 Shares of Pacira plunged more than 15 percent this morning after the company revealed the FDA panel’s decision. Source: BioSpace Posted in BioPharma